Could a clotting factor shot save trauma patients from organ failure?
NCT ID NCT05738642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a clotting factor concentrate (4F-PCC) early to people with severe traumatic bleeding could reduce organ failure and death. 380 patients were randomly assigned to receive either standard care or standard care plus 4F-PCC within 2 hours of hospital arrival. The goal was to see if the drug improves survival and lowers the need for blood transfusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- four-factor prothrombin complex concentrate (4F-PCC)
- What this could lead to
- If it works, this could provide a new early treatment to improve survival and reduce organ failure in severe trauma patients with major bleeding.
- What could go wrong
- This is a completed trial, but results are not yet widely reported. The treatment may not significantly improve outcomes over standard care, and there is a risk of clotting complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE TRAUMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yongan Xu
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.